XKRX
215600
Market cap240mUSD
Oct 08, Last price
2,340.00KRW
1D
-1.68%
1Q
4.93%
Jan 2017
-74.50%
IPO
-71.37%
Name
SillaJen Inc
Chart & performance
P/E
—
P/S
35.04
EPS
—
Div yield, %
—
Shrs. gr., 5y
12.06%
Rev. gr., 5y
40.76%
Revenues
9.23b
+134.94%
Net income
-24.05b
L-9.34%
CFO
-22.50b
L+26.19%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SillaJen, Inc. is dedicated to the advancement and commercialization of oncolytic immunotherapy products. Its primary therapeutic candidate, Pexa-Vec, is currently undergoing Phase II clinical evaluation as a potential treatment for late-stage liver cancer. The firm also has JX-970 in development, aimed at targeting tumor tissues, and the JX-900 series, which consists of modified vaccinia vaccines. Established in 2006, SillaJen is headquartered in Seoul, South Korea.
Key people
President · since 2022
Jae Gyeong Kim
Chief Executive Officer, Director · since 2022
Sang Gyu Han
Managing Director · since 2024
Mun Gi Choi
Assistant Managing Director · since 2022
Eun Su Kim
Internal Auditor · since 2025
Geun Hui Oh
Assistant Managing Director
Susanna Shin
Assistant Managing Director · since 2024
Sang Geun Park
Managing Director · since 2021
Yong Jae Jang
Non-Executive Independent Director · since 2022
Byeong Wuk Jung
Non-Executive Independent Director · since 2022
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||